New combo aims to keep advanced lung cancer in check

NCT ID NCT07141264

Recruiting now Disease control Sponsor: Tang-Du Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining the immunotherapy drug adebrelimab with the chemotherapy drug etoposide (as capsules) can help control extensive-stage small cell lung cancer after initial treatment. About 32 adults in China will receive the combination every three weeks until their cancer worsens. The goal is to see if this maintenance therapy extends the time before the disease progresses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Adebrelimab (an immunotherapy drug) combined with etoposide capsules (a chemotherapy drug)
What this could lead to: If successful, this could offer a new maintenance therapy option to help control extensive-stage small cell lung cancer and delay its progression.
What could go wrong: This is a small, early-phase (Phase 2) exploratory study with only 32 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCLC, EXTENSIVE STAGE

Contacts and locations

Locations

Tangdu Hospital Affiliated to the Fourth Military Medical University
RECRUITING

Xi'an, Shannxi, 710000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.